The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer - Test2 - elhamkhani - TriplyDB

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

http://www.wikidata.org/entity/Q26738516

about

Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer.Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism Spatial and temporal profile of cisplatin delivery by ultrasound-assisted intravesical chemotherapy in a bladder cancer model.Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis.

P2860

Q37616492-1D461144-FFA6-47F5-97F3-EF2628A8D5E4 Q39457058-CC1C3B32-896B-431C-918C-E89088C95446 Q40977936-D431A6E5-4AB2-4002-85CB-E3A65286B5E5 Q47126818-95DA3A0E-0AC3-40DE-81FF-2D1C1C20401C Q55249861-637FC562-2BF5-4029-8A5F-DBFB5CBB647F

P2860

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

http://www.wikidata.org/entity/Q26738516

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@ast

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@en

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@nl

type

label

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@ast

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@en

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@nl

prefLabel

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@ast

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@en

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@nl

P1433

Q26738516-C63AF9B9-C595-4BF5-B561-41695DCBE020

P1476

Q26738516-60D43BE3-3B92-40F8-8C59-155247A56026

P2093

Q26738516-3F4B5529-6EEA-4939-8A75-48F9EB10B7B7

Q26738516-9ECE5F78-D165-417B-8687-B1FF471263C8

P2860

Q26738516-01C321FD-50DA-4A57-8474-4DAC6243B32A

Q26738516-03E44665-C167-495A-8C9A-515B5649E7FC

Q26738516-20695E6E-4ACD-4D8D-9F9D-451DB307AA8C

Q26738516-21BC24F5-9CBE-4185-89FE-8B801C39DC03

Q26738516-25AFF063-E7F3-46D7-B1ED-E9E1731F978A

Q26738516-25CD09B5-340C-4017-802C-9587F41D1F6C

Q26738516-47B8825D-2AD7-4B38-8302-3D32A1A9B31E

Q26738516-49502778-F433-4A1E-B81B-439991A39D01

Q26738516-4D4E7D17-A837-4B42-82D7-4081C3C16FA5

Q26738516-4D4FE48A-A468-4D38-B5A5-CD2448EE8291

P304

Q26738516-024DA12C-4D86-4585-8B78-7C8B4D4B7ECB

P31

Q26738516-F0527280-53F0-4E7B-9580-F30DDFE9BD9D

P3181

Q26738516-34D7406C-F1A2-458D-9FC5-B90F7726AC7E

P356

Q26738516-9AD31E6B-2175-458D-A42F-F127FE8E41CA

P407

Q26738516-85545EAD-7047-4194-9E42-7F1CA38DEF85

P433

Q26738516-11EB87C2-EE6D-4B30-ADE1-D7945075A134

P478

Q26738516-AC5A785F-A407-4FC4-AAFA-A845A0BB6568

P577

Q26738516-23DD5AC7-7538-4BC6-A24B-059BDA5C74F2

P698

Q26738516-0F35369D-F8F3-4040-BA74-B7ABB392CC90

P921

Q26738516-33299CFF-3B80-4EB1-9083-81BD74D73886

P932

Q26738516-6AA4A14A-140A-415D-9FAE-B6119775EB70

P3181

P356

P1433

Bladder Cancer (Amsterdam, Netherlands)

P1476

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

@en

P2093

Laura Douglass

http://www.w3.org/2001/XMLSchema#string

Mark Schoenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Bladder uptake of liposomes after intravesical administration occurs by endocytosis

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

The use of a novel reverse thermosensitive polymer to prevent ureteral stone retropulsion during intracorporeal lithotripsy: a randomized, controlled trial.

The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.

Single compartment drug delivery.

Magnetic fluid hyperthermia for bladder cancer: a preclinical dosimetry study.

Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.

A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guérin in the treatment of bladder cancer.

Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

P304

285-292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4276733

http://www.w3.org/2001/XMLSchema#string

P356

10.3233/BLC-160056

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27500196

http://www.w3.org/2001/XMLSchema#string

P921

P932

4969694

http://www.w3.org/2001/XMLSchema#string